2024
Enhanced Chronic Inflammation and Increased Branched-Chain Amino Acids in Adrenal Disorders: A Cross-Sectional Study
Kittithaworn A, Dogra P, Saini J, Gruppen E, Atkinson E, Achenbach S, Yu K, Thangamuthu K, Connelly M, Dullaart R, Bancos I. Enhanced Chronic Inflammation and Increased Branched-Chain Amino Acids in Adrenal Disorders: A Cross-Sectional Study. The Journal Of Clinical Endocrinology & Metabolism 2024, 110: e330-e338. PMID: 38546526, PMCID: PMC11747673, DOI: 10.1210/clinem/dgae204.Peer-Reviewed Original ResearchMild autonomous cortisol secretionBranched-chain amino acidsMalignant adrenal massesNonfunctioning adenomasCushing's syndromeAdrenocortical carcinomaAdrenal massPrimary aldosteronismAdrenal disordersIncreasing TMAONon-functioning adrenal massesIncreased branched-chain amino acidsIncreased BCAACross-sectional study of patientsReference subjectsSingle-center cross-sectional studyAutonomous cortisol secretionTrimethylamine N-oxideKetone bodiesAdrenal hormone excessSimilar to patientsMultivariate logistic analysisIncreased cardiovascular riskMetabolite trimethylamine N-oxideStudy of patients
2019
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer
Wang L, Gong Y, Saci A, Szabo P, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack E, Sfakianos J, Bhardwaj N, Horowitz A, Farkas A, Mulholland D, Fischer B, Oh W, Sharma P, Zhu J, Galsky M. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. European Urology 2019, 76: 599-603. PMID: 31272788, PMCID: PMC6801024, DOI: 10.1016/j.eururo.2019.06.025.Peer-Reviewed Original ResearchConceptsT cell infiltrationUrothelial cancerFGFR3 mutationsAssociated with decreased T-cell infiltrationFGFR3 alterationsResponse to PD-1/PD-L1 blockadeLow T-cell infiltrationPD-1/PD-L1 inhibitionPoor T-cell infiltrationPD-1/PD-L1 blockadeResponse rateMetastatic urothelial cancerSingle-agent activityPD-1/PD-L1Tumor mutational burdenNon-cross-resistantTumors harboring mutationsFGFR3 mutation statusHypothesis-generating dataSimilar to patientsResponse to treatmentBiomarkers of resistanceGrowth factor-betaStatistically significant differenceMetastatic UC
2017
Impact of flow, gradient, and left ventricular function on outcomes after transcatheter aortic valve replacement
Carreras E, Kaneko T, Val F, Pelletier M, Sobieszczyk P, Bhatt D, Shah P. Impact of flow, gradient, and left ventricular function on outcomes after transcatheter aortic valve replacement. Catheterization And Cardiovascular Interventions 2017, 91: 798-805. PMID: 28988432, PMCID: PMC5849510, DOI: 10.1002/ccd.27347.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisBostonFemaleHeart FailureHospital MortalityHumansLength of StayMaleRecovery of FunctionRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexStroke VolumeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeVentricular Dysfunction, LeftVentricular Function, LeftConceptsTranscatheter aortic valve replacementAortic valve replacementStroke volume indexHeart failureReduced LVEFValve replacementIncreased MortalityOutcomes similar to patientsTranscatheter aortic valve replacement patientsPredictor of 1-year mortalityAssociated with increased mortalityOutcomes of patientsLeft ventricular functionSimilar to patientsReduced EFVentricular functionLVEFClinical factorsWomen's HospitalVolume indexPatientsAssociated with increasesMortalityTranscatheterOutcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply